Familial Hypercholesterolemia, FH

UK Medicines Regulator Awards Innovation Passport...
Feb. 15, 2023

Verve Therapeutics announced yesterday that its most advanced base-editing candidate VERVE-101 has been awarded the Innovation Passport for the...

First Patient Is Dosed With Base Editor to Treat...
Aug. 17, 2022

Verve Therapeutics recently announced the first human dosing with VERVE-101, an investigational base-editing therapy that is designed to treat...

Clinical Update: Base-Editing Cholesterol-Reducing...
May. 18, 2022

Verve Therapeutics announced last week that its clinical trial application for VERVE-101 in heterozygous familial hypercholesterolemia had been...

Familial Hypercholesterolemia, FH

Familial Hypercholesterolemia, FH, (NCT05398029)
Sponsors:
Verve Therapeutics, Inc.,
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine